Vonafexor is under clinical development by Enyo Pharma and currently in Phase II for Alport Syndrome. According to GlobalData, Phase II drugs for Alport Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vonafexor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vonafexor overview

EYP-001 (PXL-007) is under development for the treatment of Alport syndrome, autosomal dominant polycystic kidney disease, chronic kidney disease and non-alcoholic steatohepatitis (NASH). The drug candidate is administered through oral route as tablet, capsule and solution. It acts by targeting FXR (farnesoid X) receptor. It was also under development for the treatment of type 2 diabetes and chronic hepatitis B.

Enyo Pharma overview

Enyo Pharma is a biopharmaceutical company that develops innovative therapeutics based on fibrinolytic and anti-inflammatory properties for impaired kidney function diseases. The company’s pipeline products include vonafexor (EYP001) a synthetic non-steroidal, non-bile acid NR1H4 agonist that treats alport syndrome; EYP651 targets chronic kidney disease and nonalcoholic steatohepatitis; and EYP651 treats diabetic kidney disease. It works in partnership with the Swiss Institute of Bioinformatics, Novadiscovery and Charles River Laboratories International, among others. Enyo Pharma is headquartered in Lyon, Rhone Alpes, France.

For a complete picture of Vonafexor’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.